- Personalised chemotherapy based on tumour marker decline in poor prog…
Number of the records: 1  

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial

  1. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. In Onkológia. ISSN 1336-8176. Bratislava : SOLEN, 2015, 2015, roč. 10, č. 1, s. 60.
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.

Accept allSettingsReject all